Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18449
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNikas, S. N.en
dc.contributor.authorDrosos, A. A.en
dc.date.accessioned2015-11-24T18:52:53Z-
dc.date.available2015-11-24T18:52:53Z-
dc.identifier.issn1472-4472-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18449-
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectArthritis, Rheumatoid/drug therapyen
dc.subjectClinical Trials, Phase I as Topicen
dc.subjectClinical Trials, Phase II as Topicen
dc.subjectEnzyme Inhibitors/metabolism/pharmacology/*therapeutic useen
dc.subjectHumansen
dc.subjectIndoles/metabolism/pharmacology/*therapeutic useen
dc.subjectStructure-Activity Relationshipen
dc.subjectp38 Mitogen-Activated Protein Kinases/*antagonists & inhibitorsen
dc.titleSCIO-469 Scios Incen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15573872-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2004-
heal.abstractSCIO-469 is a small-molecule p38 mitogen-activated protein (MAP) kinase inhibitor under development by Scios Inc as a potential oral therapy for inflammatory disorders. By July 2004, SCIO-469 was in phase lib clinical trials for rheumatoid arthritis.en
heal.journalNameCurr Opin Investig Drugsen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons